1. Home
  2. AIRS vs IPHA Comparison

AIRS vs IPHA Comparison

Compare AIRS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AirSculpt Technologies Inc.

AIRS

AirSculpt Technologies Inc.

SELL

Current Price

$1.50

Market Cap

182.4M

Sector

Health Care

ML Signal

SELL

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

BUY

Current Price

$1.48

Market Cap

165.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
AIRS
IPHA
Founded
2012
1999
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.4M
165.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
AIRS
IPHA
Price
$1.50
$1.48
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$4.50
★ $6.67
AVG Volume (30 Days)
★ 853.8K
55.5K
Earning Date
11-06-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $151,818,000.00
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
$2.65
$143.06
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.51
$1.17
52 Week High
$12.00
$2.71

Technical Indicators

Market Signals
Indicator
AIRS
IPHA
Relative Strength Index (RSI) 27.18 31.54
Support Level N/A $1.34
Resistance Level $2.03 $1.83
Average True Range (ATR) 0.13 0.10
MACD 0.01 -0.01
Stochastic Oscillator 0.79 0.00

Price Performance

Historical Comparison
AIRS
IPHA

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: